Pulmonary Mucormycosis Mimicking a Lung Tumor in a Patient with Advanced Retroviral Disease DOI Open Access

Shuk Ching Chai,

Khai Lip Ng,

Nai Chien Huan

et al.

Respiratory Case Reports, Journal Year: 2024, Volume and Issue: 13(1), P. 20 - 24

Published: Jan. 1, 2024

Pulmonary mucormycosis is a relatively rare disease that may become more common with the increasing number of immunocompromised patients.The male case presented here, advanced retroviral disease, persistent cough and acute respiratory distress.A chest radiograph computed tomography (CT) thorax revealed right apical pneumothorax mass in main bronchus.Flexible bronchoscopy an endobronchial mass, occluded entirely bronchus.Histopathological examinations multiple biopsies fungal bodies suggestive mucormycosis.The patient was treated Posaconazole, leading to complete clinical radiological cure.

Language: Английский

Molecular architecture of chitin and chitosan-dominated cell walls in zygomycetous fungal pathogens by solid-state NMR DOI Creative Commons

Qinghui Cheng,

Malitha C. Dickwella Widanage, Jayasubba Reddy Yarava

et al.

Nature Communications, Journal Year: 2024, Volume and Issue: 15(1)

Published: Sept. 27, 2024

Language: Английский

Citations

7

Co-Occurrence of Gram-Negative Rods in Patients with Hematologic Malignancy and Sinopulmonary Mucormycosis DOI Creative Commons
Stephanie L Egge, Sebastian Wurster, Sung‐Yeon Cho

et al.

Journal of Fungi, Journal Year: 2024, Volume and Issue: 10(1), P. 41 - 41

Published: Jan. 4, 2024

Both Mucorales and Gram-negative rods (GNRs) commonly infect patients with hematological malignancies (HM); however, their co-occurrence is understudied. Therefore, we retrospectively reviewed the records of 63 HM proven or probable sinopulmonary mucormycosis at MD Anderson Cancer Center (Houston, Texas) from 2000-2020. Seventeen out sixty-three (27.0%) had GNRs (most

Language: Английский

Citations

5

Infección osteoarticular DOI
Tristan Ferry, Cécile Batailler, Céline Dupieux

et al.

EMC - Tratado de Medicina, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Citations

0

Mixed fungal infection of Actinomucor elegans and Aspergillus fumigatus in a person with severe fever with thrombocytopenia syndrome DOI

Lu Ren,

Zhen Liu, Jian Wang

et al.

Diagnostic Microbiology and Infectious Disease, Journal Year: 2025, Volume and Issue: 112(1), P. 116750 - 116750

Published: Feb. 15, 2025

Language: Английский

Citations

0

A humanized antibody against mucormycosis targets angioinvasion and augments the host immune response DOI
Yiyou Gu, Shakti Singh, Abdullah Alqarihi

et al.

Science Translational Medicine, Journal Year: 2025, Volume and Issue: 17(789)

Published: March 12, 2025

Mucormycosis is a fungal infection caused by Mucorales fungi that cause severe disease and fatality, especially in immunocompromised individuals. Although vaccines immunotherapeutics have been successful combating viral bacterial infections, approved antifungal immunotherapies are yet to be realized. To address this gap, monoclonal antibodies targeting invasive infections emerged as promising approach, particularly for patients who unlikely maximally benefit from vaccines. The spore coat (CotH) proteins identified crucial invasins bind glucose-regulated protein 78 (GRP78) integrins of host barrier cells. Previously, we described murine antibody, anti-CotH C2, which protected diabetic ketoacidosis (DKA) neutropenic mice mucormycosis. Here, advanced the development C2 immunoglobulin G1 (IgG1) humanizing it, establishing stable Chinese hamster ovary cell line producing antibody at commercial yields, carried out optimization upstream downstream manufacturing processes. resultant humanized IgG1 (VX-01) exhibited 10-fold increase binding affinity CotH conferred comparable vitro vivo efficacy when compared antibody. mechanism protection was reliant on prevention angioinvasion enhancing opsonophagocytic killing. VX-01 demonstrated acceptable safety profiles with no detectable damage cells weak or moderate only cytoplasmic ex good laboratory practice–human tissue cross-reactivity studies. Our studies warrant continued adjunctive immunotherapy.

Language: Английский

Citations

0

A diabetic individual with post-COVID-19 mucormycosis complicated by severe myiasis: a case report DOI Creative Commons

S. Sethuraman,

Anita Michael,

Arun Sakthivel

et al.

Bulletin of the National Research Centre/Bulletin of the National Research Center, Journal Year: 2025, Volume and Issue: 49(1)

Published: March 20, 2025

Abstract Myiasis is a tropical parasitic infestation prevalent among individuals with poor living conditions and immunocompromised states. We present unique case of nasal oral myiasis in patient diabetes mellitus post-COVID-19 mucormycosis. Contrary to existing literature, this exhibited well-controlled mellitus, maintained through regular follow-ups strict medication adherence. To our knowledge, controlled has not been previously documented. This report may thus provide valuable insights for physicians evaluating patients post-mucormycosis status, irrespective environmental or medical factors. Our study details the 71-year-old male history who presented persistent dry cough, bleeding, right-sided facial pain swelling, intermittent right temporal headache. The had known COVID-19-associated mucormycosis undergone dental procedure six months prior. Oral cavity examination revealed erosion teeth on side, migrating maggot larvae upper third molar space, site previous extraction. He was managed conservatively analgesics turpentine oil. Endoscopic removal maggots attempted, single dose systemic Ivermectin given, prophylactic antibiotics were prescribed. improved symptomatically discharged. suggests that alone can be potential risk factor myiasis, therefore, follow-up, early diagnosis, intervention status are necessary.

Language: Английский

Citations

0

Neonatal Mucormycosis: A Rare but Highly Lethal Fungal Infection in Term and Preterm Newborns—A 20-Year Systematic Review DOI Creative Commons

Alfredo Valdez-Martinez,

Mónica Ingrid Santoyo-Alejandre,

Roberto Arenas

et al.

Tropical Medicine and Infectious Disease, Journal Year: 2025, Volume and Issue: 10(4), P. 86 - 86

Published: March 24, 2025

Background/Objectives: Mucormycosis is a rare but life-threatening fungal infection, particularly in neonates, due to their undeveloped immune system. This systematic review aims analyze the risk factors, clinical presentations, treatments, and outcomes of neonatal mucormycosis reported between 2004 2024. Methods: A literature search was conducted PubMed, Scopus, Web Science following PRISMA guidelines. Only studies reporting cases neonates (≤28 days old) were included. Data on features, diagnostic methods, antifungal therapies, surgical interventions, extracted analyzed. Results: total 44 met inclusion criteria, comprising 61 cases. The most common presentations gastrointestinal (n = 39), cutaneous 19), rhino-orbito-cerebral 2), disseminated 1). Diagnosis primarily based histopathology (93.4%) culture (26.2%). main treatment liposomal amphotericin B (63.9%), often combined with debridement (60.6%). Mortality rates remained high (47.5%), prematurely extreme angioinvasive disease or delayed diagnosis. Conclusions: Neonatal remains severe condition morbidity mortality. Early diagnosis through combination suspicion laboratory confirmation, along prompt therapy management, apparently crucial for improving outcomes. Further are needed optimize strategies improve survival.

Language: Английский

Citations

0

Real-World Effectiveness and Safety of Isavuconazole Versus Amphotericin B for Patients with Invasive Mucormycosis DOI Creative Commons
Jiayuan Qin,

Hongxia Bi,

Guangmin Tang

et al.

Microorganisms, Journal Year: 2025, Volume and Issue: 13(1), P. 55 - 55

Published: Jan. 1, 2025

Background: Invasive mucormycosis (IM) poses a substantial morbidity and mortality burden among immunocompromised patients. Objectives: We aim to compare the real-world effectiveness safety of isavuconazole with those amphotericin B in patients IM. Patients methods: In this observational cohort study, we enrolled who were diagnosed IM treated either or B. Results: A total 106 met study criteria. Of these, 47 received isavuconazole, 59 as primary treatment. The two cohorts had similar baseline characteristics, including history malignancy, use immunosuppressants, infection sites, pathogens. group demonstrated significantly greater incidence renal disorders (p < 0.001) hypokalemia than group. proportion salvage therapy was (42% vs. 6%, p 0.001). Eighteen discontinued treatment because adverse events, whereas no events. significant difference therapeutic response between groups noted = 0.013), higher failure rate (68% 36%, However, there differences all-cause mucormycosis-attributable rates groups. Conclusions: Isavuconazole outperformed first-line option for terms its clinical safety.

Language: Английский

Citations

0

Violaceous Nodules on the Left Forearm of an Immunosuppressed Patient Following Heart Transplantation for Cardiac Amyloidosis DOI Creative Commons
Zachary Corey, Lydia A. Luu, Sabrina Newman

et al.

Dermatopathology, Journal Year: 2025, Volume and Issue: 12(1), P. 2 - 2

Published: Jan. 16, 2025

We present the case of a 60-year-old immunocompromised man who presented with two pruritic pink–red indurated nodules overlying scale and focal areas ulceration on his left dorsal medial forearm, which evolved over 2-month period. The pathology showed numerous fungal hyphae that were pauci-septate various branched angles variable hyphal thickness. Fungal cultures grew Rhizopus species universal PCR detected oryzae complex. Based clinicopathologic correlation, diagnosis cutaneous mucormycosis was made. Cutaneous is an aggressive infection Mucorales family occurring after inoculation spores in disrupted skin. It usually presents as necrotic eschar but can also cellulitis evolves into ulcer. A prompt critical for effective management mucormycosis. treatment includes immediate systemic amphotericin B surgical debridement regions. Given wide range presenting symptoms, clinical suspicion this emergent condition must remain high diabetic patients.

Language: Английский

Citations

0

The Contribution of Human Antimicrobial Peptides to Fungi DOI Open Access

Qiaoxi Zhang,

Ki Ryung Choi,

Xiaoyue Wang

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(6), P. 2494 - 2494

Published: March 11, 2025

Various species of fungi can be detected in the environment and within human body, many which may become pathogenic under specific conditions, leading to various forms fungal infections. Antimicrobial peptides (AMPs) are evolutionarily ancient components immune response that quickly induced infections with pathogens almost all tissues. There is a wide range AMP classes humans, exhibit broad-spectrum antimicrobial function. This review provides comprehensive overview mechanisms action AMPs, their distribution antifungal activity against both common rare clinical pathogens. It also discusses current research status promising novel strategies, highlighting challenges must overcome development these therapies. The hope peptides, as class agents, will soon progress through large-scale trials implemented practice, offering new treatment options for patients suffering from

Language: Английский

Citations

0